Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2008

01-02-2008 | Gastrointestinal Oncology

Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients

Authors: Natalie G. Coburn, MD, MPH, Anand Govindarajan, MD, MSc, Calvin H. L. Law, MD, MPH, Ulrich Guller, MD, MHS, Alex Kiss, PhD, Jolie Ringash, MD, Carol J. Swallow, MD, PhD, Nancy N. Baxter, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2008

Login to get access

Abstract

Background

Adjuvant chemoradiotherapy improved survival in patients with resected gastric adenocarcinoma in the Southwest Oncology Group/Intergroup 0116 trial. Our objective was to examine the impact of adjuvant treatment on overall survival (OS) in the general population.

Methods

Patients 18–85 years old who had undergone resection of non-metastatic gastric adenocarcinoma between May 2000 and December 2003, were identified from the Surveillance Epidemiology and End Results (SEER) database. Patients who had received pre-operative irradiation, had unknown stage or radiation status, or had a survival of 3 months or less from the date of diagnosis were excluded. Survival of those who received post-operative irradiation was compared with those who did not; Kaplan-Meier methods and Cox proportional hazards models were used.

Results

Of 4,041 patients, there was improved survival for those receiving adjuvant irradiation for stages III and IVM0, with a median OS of 31 versus 24 months (P = 0.005) and 20 versus 15 months (P < 0.001), respectively, and a trend for improved survival in univariate analysis of stage II (P = 0.0535). In final adjusted analysis, adjuvant irradiation significantly improved OS in stages III (HR: 0.71, P = 0.0007) and IVM0 (HR: 0.66, P < 0.0001). Adjusted analysis using a propensity score suggested that the benefit of adjuvant irradiation was similar in stage-II and -III patients. However, there was no statistical improvement in survival for stage-Ib and -II patients who had received adjuvant irradiation.

Conclusions

In this population-based analysis, adjuvant radiotherapy for stage-III and IVM0 gastric cancer significantly improved OS. Analysis of stage-Ib and -II patients is limited by small numbers, but there may not be the same benefit.
Literature
1.
2.
Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000;88:921–32PubMedCrossRef
3.
Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Jr., Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583–92PubMedCrossRef
4.
Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059–64PubMedCrossRef
5.
Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994;343:1309–12PubMedCrossRef
6.
Hermans J, Bonenkamp JJ, Boon MC, Bunt A, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441–7PubMed
7.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30PubMedCrossRef
8.
Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000;11:837–43PubMedCrossRef
9.
Moertel CG, Childs DS, O’Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984;2:1249–54PubMed
10.
11.
12.
13.
Kassam Z, Lockwood G, O’Brien C, et al. Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. Int J Radiat Oncol Biol Phys 2006;65:713–9PubMed
14.
Hughes B, Yip D, Chao M, Gibbs P, Carroll S, Goldstein D, et al. Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. ANZ J Surg 2004;74:951–6PubMedCrossRef
15.
Kelsen DP. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol 2000;18:32S–34SPubMed
16.
Macdonald J, Smalley S, Benedetti J et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). [Abstract]. 2004 Gastrointestinal Cancers Symposium 2007
17.
American Joint Committee on Cancer Staging Manual. JB. Lippincott, Philadelphia, 1997
18.
Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol 2002;80:181–5PubMedCrossRef
19.
So JB, Yam A, Cheah WK, Kum CK, Goh PM. Risk factors related to operative mortality and morbidity in patients undergoing emergency gastrectomy. Br J Surg 2000;87:1702–7PubMedCrossRef
20.
21.
Hundahl S. Eliminating and suppressing local-regional disease in gastric cancer. J Surg Oncol 2005;90:171–3PubMedCrossRef
22.
Lordick F, Siewert J. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005;8:78–85PubMedCrossRef
23.
Harrell Jr. F. Regression modelling strategies with applications to linear models, logistic regression, and survival analysis (Springer Series in Statistics). Springer-Verlag, New York, 2002
24.
Coburn NG, Guller U, Baxter NN, Kiss A, Ringash J, Swallow C, Law CHL. Adjuvant Therapy for Resected Gastric Cancer—Rapid, yet Variable Adoption Following the Results of the Intergroup 0116 Trial. 2007. Ref Type: Unpublished Work
25.
Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516–24CrossRef
26.
de Gara C, Hanson J, Hamilton S. A population-based study of tumor-node relationship, resection margins, and surgeon volume on gastric cancer survival. Am J Surg 2003;186:23–7PubMed
27.
Chemotherapy and radiation therapy after surgery in treating patients with stomach or esophageal cancer. ClinicalTrials.gov Identifier NCT00052910. National Cancer Institute. 2007. Ref Type: Electronic Citation
28.
Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143–51PubMedCrossRef
29.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRef
Metadata
Title
Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients
Authors
Natalie G. Coburn, MD, MPH
Anand Govindarajan, MD, MSc
Calvin H. L. Law, MD, MPH
Ulrich Guller, MD, MHS
Alex Kiss, PhD
Jolie Ringash, MD
Carol J. Swallow, MD, PhD
Nancy N. Baxter, MD, PhD
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9640-0

Other articles of this Issue 2/2008

Annals of Surgical Oncology 2/2008 Go to the issue

Gastrointestinal Oncology

Impact of the Site of Anastomosis after Oncologic Esophagectomy on Quality of Life — A Prospective, Longitudinal Outcome Study

Gynecologic Oncology

Fluorescence in situ Hybridization and Immunohistochemical Analysis of p53 Expression in Endometrial Cancer: Prognostic Value and Relation to Ploidy

Endocrine Tumors

Laparoscopic Resection of Extraadrenal Pheochromocytoma

Hepatic and Pancreatic Tumors

Prognostic Factors and Optimal Treatment Strategy for Intrahepatic Nodular Recurrence After Curative Resection of Hepatocellular Carcinoma

Gastrointestinal Oncology

Serum Cytokeratin 19 Fragment (CYFRA21-1) as a Prognostic Factor in Intrahepatic Cholangiocarcinoma

Endocrine Tumors

Value of Intraoperative Parathyroid Hormone Monitoring